← back to search

Marco Carbone

Istituti di Ricovero e Cura a Carattere Scientifico · IT
Area of research
Hepatology · Epidemiology
Research interest
Research interests include Liver Diseases and Immunity, Liver Disease Diagnosis and Treatment, Pediatric Hepatobiliary Diseases and Treatments, and Gallbladder and Bile Duct Disorders.
h-index
42
citations
6,594
works
331
NIH funding
primary concept
Medicine
email

Recent publications

Non-Response to Obeticholic Acid Is Associated With Heightened Risks of Developing Clinical Events in Primary Biliary Cholangitis.
2026cited by 2position: contributordoi
Diagnostic Yield of Whole Exome Sequencing in Adult-onset Cholestatic Liver Disease.
2026cited by 0position: contributordoi
Cholangiocarcinoma 2026: status quo, unmet needs and priorities
Nature Reviews Gastroenterology & Hepatology 2025cited by 30position: middledoi
Trends in Primary Biliary Cholangitis: Prospective Cohort Study From the European Reference Network Registry (R-LIVER).
2025cited by 2position: contributordoi
Quality Measures to Enhance the Management and Treatment of Primary Biliary Cholangitis: A Delphi Consensus Study
Liver International 2025cited by 1position: middledoi
Diagnosing Autoimmune Hepatitis: Histological Correlations and Emerging Technologies.
2025cited by 1position: contributordoi
Noninvasive Assessment of Portal Hypertension in Patients With Primary Biliary Cholangitis Is Affected by Severity of Cholestasis.
2025cited by 1position: contributordoi
Fibrate-Oca (FI-OCA) Study - a Global snapshot of PBC practice around the Globe
Digestive and Liver Disease 2025cited by 0position: lastdoi
Primary biliary cholangitis (PBC): evolving approaches and expert perspectives
Expert Review of Gastroenterology & Hepatology 2025cited by 0position: middledoi
Improving Primary Biliary Cholangitis Outcomes in the Evolving Landscape of Second-Line Therapies.
2025cited by 0position: contributordoi
Quality Measures to Enhance the Management and Treatment of Primary Biliary Cholangitis: A Delphi Consensus Study.
2025cited by 0position: contributordoi
Dynamics of Liver Stiffness Measurement and Clinical Course of Primary Biliary Cholangitis
Clinical Gastroenterology and Hepatology 2024cited by 28position: middledoi
Primary biliary cholangitis drug evaluation and regulatory approval: Where do we go from here?
2024cited by 25position: contributordoi
Deep learning helps discriminate between autoimmune hepatitis and primary biliary cholangitis
JHEP Reports 2024cited by 15position: middledoi
Loss of biochemical response at any time worsens outcomes in UDCA-treated patients with primary biliary cholangitis
JHEP Reports 2024cited by 13position: middledoi
Position paper of the Italian Association for the Study of the Liver (AISF): Management and treatment of primary biliary cholangitis
Digestive and Liver Disease 2024cited by 11position: firstdoi
Development and Validation of a Scoring System to Predict Response to Obeticholic Acid in Primary Biliary Cholangitis
Clinical Gastroenterology and Hepatology 2024cited by 9position: middledoi
Development and Validation of a Scoring System to Predict Response to Obeticholic Acid in Primary Biliary Cholangitis.
2024cited by 7position: contributordoi
Noninvasive Assessment of Portal Hypertension in Patients With Primary Biliary Cholangitis Is Affected by Severity of Cholestasis
Clinical Gastroenterology and Hepatology 2024cited by 4position: lastdoi
Longer transplant-free and liver-related event-free survival in obeticholic acid-treated patients with primary biliary cholangitis compared to external controls from two large real-world cohorts
Digestive and Liver Disease 2024cited by 3position: middledoi
Improving predictive accuracy in primary biliary cholangitis: A new genetic risk score.
2024cited by 3position: contributordoi
Biochemical response to obeticholic acid drives liver stiffness variation over time and the risk of liver-related events in patients with primary biliary cholangitis
Digestive and Liver Disease 2024cited by 0position: middledoi
Adequate versus deep response to ursodeoxycholic acid in primary biliary cholangitis: To what extent and under what conditions is normal alkaline phosphatase level associated with complication-free survival gain?
Hepatology 2023cited by 74position: middledoi
Setanaxib, a first‐in‐class selective NADPH oxidase 1/4 inhibitor for primary biliary cholangitis: A randomized, placebo‐controlled, phase 2 trial
Liver International 2023cited by 64position: middledoi
Setanaxib, a first-in-class selective NADPH oxidase 1/4 inhibitor for primary biliary cholangitis: A randomized, placebo-controlled, phase 2 trial.
2023cited by 46position: contributordoi
Liver Transplantation for Primary Sclerosing Cholangitis (PSC) With or Without Inflammatory Bowel Disease (IBD)—A European Society of Organ Transplantation (ESOT) Consensus Statement
Transplant International 2023cited by 38position: firstdoi
Artificial Intelligence and liver: Opportunities and barriers
Digestive and Liver Disease 2023cited by 36position: middledoi
Intensive care management of acute-on-chronic liver failure
Intensive Care Medicine 2023cited by 34position: lastdoi
Impact of setanaxib on quality of life outcomes in primary biliary cholangitis in a phase 2 randomized controlled trial
Hepatology Communications 2023cited by 33position: middledoi
A quantitative MRCP-derived score for medium-term outcome prediction in primary sclerosing cholangitis
Digestive and Liver Disease 2023cited by 31position: contributordoi

Grants

No grants ingested yet.

Frequent collaborators

· 24 papers (2019–2026)Pietro Invernizzi · University Health Network17 papers (2019–2026)Pietro Invernizzi · University Health Network16 papers (2016–2025)Nora Cazzagon · IRCCS Humanitas Research Hospital12 papers (2018–2025)Marco Marzioni · University of Bologna10 papers (2016–2025)Annarosa Floreani · Ospedale Sacro Cuore Don Calabria10 papers (2017–2022)Domenico Alvaro · European Association for the Study of Diabetes9 papers (2016–2025)Alessio Gerussi · St Olav's University Hospital8 papers (2020–2024)Cristina Rigamonti · University of Bologna7 papers (2020–2025)Keith D. Lindor · Mayo Clinic6 papers (2019–2023)Umberto Vespasiani‐Gentilucci · Università Campus Bio-Medico5 papers (2017–2025)Laura Cristoferi · University of Milano-Bicocca5 papers (2020–2023) · 5 papers (2016–2020) · 5 papers (2020–2025)Ana Lleo · Istituti di Ricovero e Cura a Carattere Scientifico5 papers (2022–2025)Vincenza Calvaruso · Azienda Ospedaliera Universitaria Policlinico "Paolo Giaccone" di Palermo5 papers (2022–2025)M. Eric Gershwin · Joe DiMaggio Children's Hospital4 papers (2016–2019)Fabio Piscaglia · Ludwig-Maximilians-Universität München4 papers (2016–2025)Christophe Corpechot · University Health Network4 papers (2019–2021)David Jones · Newcastle upon Tyne Hospital4 papers (2020–2023)